Clinical Trial

Acute Olanzapine and Lipid Response

Study Description

Acute Olanzapine and Lipid Response

Atypical antipsychotics are pharmaceutical drugs used to treat schizophrenia. Common side effects are weight gain, insulin resistance, and abnormal blood lipids. This increases the risk for type 2 diabetes and cardiovascular disease in patients taking these drugs. In particular, olanzapine is a highly effective therapy for schizophrenia but is commonly associated with metabolic disturbances. It has previously been shown that the negative effects on insulin sensitivity and glucose metabolism occur even after a single dose, independently of weight gain. These effects may be mediated by blocking the dopamine (D2) receptor. In this study the research team is investigating whether a single dose of olanzapine alters postprandial lipid metabolism after a high-fat drink. Olanzapine administered along with the high-fat drink will be compared to placebo or olanzapine plus bromocriptine (an activator of the D2 receptor).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Olanzapine 10 milligram

Oral olanzapine capsule

Drug - Bromocriptine 5 milligram

Oral bromocriptine capsule

Drug - Placebo oral tablet

oral placebo capsules

Additional Information

Official Study Title

Assessment of Lipid Response to Acute Olanzapine in Healthy Adults

Clinical Trial ID

NCT04181385

ParticipAid ID

eVOL5a